Hematology

Concomitant Steroids and Mogamulizumab Lead to Greater Response Rate in MF/SS, Suggests Benefit for Real-World Use

September 11, 2020

Responses were improved for patients receiving treatment with mogamulizumab with the use of concomitant topical steroids compared with the overall study population in the phase 3 MAVORIC study of patients with mycosis fungoides or Sézary syndrome, according to the results of a post hoc analysis of the study.

Modified Pediatric Regimen Improves Outcomes in Young Adult Patients With Acute Lymphoblastic Leukemia

September 09, 2020

Using a modified pediatric regimen to treat adolescents and young adults with acute lymphoblastic leukemia led to superior outcomes compared with historical adult ALL regimen results, according to a retrospective analysis that evaluated 95 AYAs aged 14 to 39 years. Findings were presented at the eighth annual Society of Hematologic Oncology virtual meeting.

Considerations for Choosing Between Newer Agents in R/R B-Cell ALL

September 09, 2020

In the past 5 years, 3 new treatment options have emerged to treat patients with relapsed or refractory acute lymphoblastic leukemia, providing hope for patients with this disease, but also raising clinical questions of how to choose among these agents and what is the best option for the patient at which time.

Targeted Therapy Combinations With JAK inhibition Show Early Promise for Myelofibrosis

August 31, 2020

Patients with myelofibrosis have complicated pathology and multiple pathways, creating the opportunity to use multiple targeted agents for treatment, but also leading to greater potential for resistance to monotherapy, according to Lucia Masarova, MD.

ODAC Continues to Make Revolutionary Drug Recommendations During COVID-19

August 29, 2020

In an interview with Targeted Oncology, Phillip C. Hoffman, MD, professor of medicine, University of Chicago, and chairperson of ODAC, discussed ODAC operations during the COVID-19 pandemic and the most recently meetings and decisions the committee has made to influence treatments options in oncology.

Rigosertib Misses Primary End Point in Phase 3 Study of Higher-Risk Myelodysplastic Syndrome

August 24, 2020

The median overall survival among patients receiving rigosertib in the intent-to-treat population was 6.4 months compared with 6.3 months with the physician’s choice as treatment of patients with higher-risk myelodysplastic syndrome.